Affimed NV AFMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AFMD is a good fit for your portfolio.
News
-
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
-
Affimed Reports 2023 Financial Results and Operational Progress
-
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
-
Affimed Announces 1-for-10 Reverse Stock Split
Trading Information
- Previous Close Price
- $5.03
- Day Range
- $4.91–5.59
- 52-Week Range
- $2.24–11.10
- Bid/Ask
- $5.28 / $5.80
- Market Cap
- $83.60 Mil
- Volume/Avg
- 104,467 / 97,172
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 78
- Website
- https://www.affimed.com
Comparables
Valuation
|
Metric
|
AFMD
|
MRUS
|
FUSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.29 | 7.32 | 7.67 |
Price/Sales | 9.16 | 52.97 | 678.96 |
Price/Cash Flow | — | — | — |
Price/Earnings
AFMD
MRUS
FUSN
Financial Strength
|
Metric
|
AFMD
|
MRUS
|
FUSN
|
|---|---|---|---|
Quick Ratio | 3.02 | 5.19 | 14.66 |
Current Ratio | 3.25 | 5.34 | 15.01 |
Interest Coverage | −57.94 | — | −19.06 |
Quick Ratio
AFMD
MRUS
FUSN
Profitability
|
Metric
|
AFMD
|
MRUS
|
FUSN
|
|---|---|---|---|
Return on Assets (Normalized) | −70.16% | −30.87% | −33.14% |
Return on Equity (Normalized) | −98.94% | −42.51% | −43.87% |
Return on Invested Capital (Normalized) | −83.25% | −44.25% | −36.42% |
Return on Assets
AFMD
MRUS
FUSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lnlksjvvb | Vlsh | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qzzghpyx | Hxldmsd | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mljsrstj | Bxtwrfb | $98.3 Bil | |
MRNA
| Moderna Inc | Qydlfhy | Wypfz | $42.7 Bil | |
ARGX
| argenx SE ADR | Whvlrrjsc | Szd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mjbnfjy | Mglw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fybgwgky | Dzrhlfr | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ngggzlbjl | Xjcyknx | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Djhttdrg | Sfvtv | $12.7 Bil | |
INCY
| Incyte Corp | Rzzpmts | Mcctcw | $11.8 Bil |